Skip to content

Breaking: Biogen sells just $300K worth of Aduhelm in Q3, as questions on long term viability remain – Endpoints News

Breaking: Biogen sells just $300K worth of Aduhelm in Q3, as questions on long term viability remain  Endpoints NewsBiogen’s New Alzheimer’s Drug Meets Slow Rollout  The Wall Street JournalBiogen’s Aduhelm sales fall dramatically below Wall Street’s expectations  STATBiogen raises forecast despite disappointing Alzheimer’s drug sales  ReutersBiogen’s Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.  Barron’sView Full Coverage on Google News

Leave a Reply

Your email address will not be published. Required fields are marked *